NasdaqCM - Nasdaq Real Time Price USD
ZyVersa Therapeutics, Inc. (ZVSA)
At close: November 6 at 4:00 PM EST
After hours: 7:23 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
10,259.5070
14,420.7740
13,013.0640
7,704.3760
11,833.0580
Operating Income
-10,259.5070
-14,420.7740
-13,013.0640
-7,704.3760
-11,833.0580
Net Non Operating Interest Income Expense
-0.4670
0.4570
-427.5420
-821.3660
-516.4500
Other Income Expense
-408.4000
-93,333.4590
-607.0010
441.5810
-333.6580
Pretax Income
-22,418.2290
-107,753.7760
-14,047.6070
-8,084.1610
-12,683.1660
Tax Provision
-586.8460
-9,455.8300
--
--
--
Net Income Common Stockholders
-21,863.7560
-106,246.1550
-24,063.4440
-8,084.1610
-12,683.1660
Diluted NI Available to Com Stockholders
-21,863.7560
-106,246.1550
-24,063.4440
-8,084.1610
-12,683.1660
Basic EPS
1.23k
-1.09k
-346.10
-139.88
-183.27
Diluted EPS
1.23k
-1.09k
-346.10
-139.88
-183.27
Basic Average Shares
442.8460
97.5030
69.2050
57.7920
69.2050
Diluted Average Shares
442.8460
97.5030
69.2050
57.7920
69.2050
Total Operating Income as Reported
-22,417.7620
-107,754.2330
-13,013.0640
-7,704.3760
-11,833.0580
Total Expenses
10,259.5070
14,420.7740
13,013.0640
7,704.3760
11,833.0580
Net Income from Continuing & Discontinued Operation
-21,831.3830
-98,297.9460
-14,047.6070
-8,084.1610
-12,683.1660
Normalized Income
-9,991.3968
-13,177.8314
-13,440.6060
-8,525.7420
-12,349.5080
Interest Income
--
0.4570
--
--
--
Interest Expense
582.5370
--
427.5420
821.3660
516.4500
Net Interest Income
-0.4670
0.4570
-427.5420
-821.3660
-516.4500
EBIT
-10,259.5070
-14,420.7740
-13,620.0650
-7,262.7950
-12,166.7160
EBITDA
-10,249.1070
-14,410.3740
-13,610.1970
-7,252.3950
-12,156.3160
Reconciled Depreciation
10.4000
10.4000
9.8680
10.4000
10.4000
Net Income from Continuing Operation Net Minority Interest
-21,831.3830
-98,297.9460
-14,047.6070
-8,084.1610
-12,683.1660
Total Unusual Items Excluding Goodwill
-12,158.2550
-93,333.4590
-607.0010
441.5810
-333.6580
Total Unusual Items
-12,158.2550
-93,333.4590
-607.0010
441.5810
-333.6580
Normalized EBITDA
1,909.1480
78,923.0850
-13,003.1960
-7,693.9760
-11,822.6580
Tax Rate for Calcs
0.0000
0.0001
--
--
--
Tax Effect of Unusual Items
-318.2688
-8,213.3444
--
--
--
12/31/2020 - 2/11/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BNOX Bionomics Limited
0.2789
-43.43%
TOVX Theriva Biologics, Inc.
1.9700
0.00%
NLSP NLS Pharmaceutics AG
4.0900
+1.24%
THAR Tharimmune, Inc.
2.8000
+1.08%
ATHA Athira Pharma, Inc.
0.7000
-6.67%
ENSC Ensysce Biosciences, Inc.
0.5503
+5.42%
GRI GRI Bio, Inc.
0.9500
-4.04%
EVGN Evogene Ltd.
1.9300
-2.03%
AVTE Aerovate Therapeutics, Inc.
2.7600
+2.22%
GLYC GlycoMimetics, Inc.
0.3765
-3.46%